Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Association of D-dimer Levels with Clinical Event Rates and the Efficacy of Betrixaban versus Enoxaparin in the APEX Trial. TH open : companion journal to thrombosis and haemostasis Gibson, C. M., Jennings, L. K., Chi, G. n., Yee, M. K., Halaby, R. n., Nafee, T. n., AlKhalfan, F. n., Kerneis, M. n., Korjian, S. n., Daaboul, Y. n., Goldhaber, S. Z., Hull, R. D., Hernandez, A. F., Cohen, A. T., Harrington, R. A. 2018; 2 (1): e16–e24

Abstract

Background Elevated D-dimer concentrations are associated with an increased risk of venous thromboembolism (VTE). However, they may also provide prognostic value. The present analysis sought to study the association of D-dimer levels with VTE event rates and the efficacy of betrixaban versus enoxaparin in the APEX trial. Methods Hospitalized acutely medically ill subjects ( n ?=?7,513) were randomized in a double-dummy double-blind fashion to either extended-duration oral betrixaban (80?mg once daily for 35-42 days) or standard dose subcutaneous enoxaparin (40?mg once daily for 10?±?4 days) for venous thromboprophylaxis. D-dimer was assessed using a central core laboratory measurement. Results For every 0.25 µg/mL increase in D-dimer concentration, there was a 2% increase in the relative risk of experiencing the primary efficacy endpoint (asymptomatic deep vein thrombosis [DVT], symptomatic DVT, nonfatal pulmonary embolism, or VTE-related death) in both the betrixaban ( p ?

View details for DOI 10.1055/s-0037-1615288

View details for PubMedID 31249924

View details for PubMedCentralID PMC6524856